Biologic Therapeutics in the Treatment of Psoriasis. Part 2: Practical Considerations

Biologics in the Treatment of Psoriasis: Clinical and Economic Overview

Background:

The use of biologic medications for psoriasis is a recent therapeutic advance.

Objective:

To review clinical and economic data for biologic therapies in the treatment of chronic plaque psoriasis.

Methods:

Published meta-analyses and additional literature review identified randomized controlled trials. Analyses included the number needed to treat (NNT), the cost in Canadian dollars for the first year of treatment per the Canadian product monograph, and the estimated cost per responder achieving a 75% reduction in Psoriasis Area and Severity Index score (PASI 75).

Results:

Pooled NNTs were 1.3 (infliximab), 1.5 (ustekinumab 90 mg), 1.6 (adalimumab and ustekinumab 45 mg), 2.3 (etanercept), 4.1 (efalizumab), and 5.6 (alefacept). The annual treatment cost per patient was $19,825 to $37,600. The cost per patient achieving a PASI 75 response at 12 weeks ranged from $8,330 (adalimumab) to $71,371 (alefacept).

Conclusion:

This analysis suggests favorable cost and benefits of biologic psoriasis therapies, particularly adalimumab, infliximab, and ustekinumab.